Buy & Sell Global Payments Inc (GPN) – Global Payments Inc Price Today
Aura AI Summary
Key Stats
- $20.66BMarket Cap
- IndustrialsSector
- -19.91%3M Drawdown
- $38.37BEnterprise Value
- 1.32%Dividend Yield
- 39% Buy | 61% SellTrading Activity
- 57 daysTypical Hold Time
Global Payments Inc (GPN) is currently valued at a market capitalization of $20.66B, with an enterprise value of $38.37B. Over the past 52 weeks, Global Payments Inc has traded between a low of $62.7 and a high of $90.01, highlighting its annual price range. Over the past three months, Global Payments Inc has recorded a drawdown of -19.91%, reflecting recent price volatility. Global Payments Inc offers a dividend yield of 1.32%, with the most recent dividend of $0.25 paid on 09 Mar 26. On average, investors hold Global Payments Inc for approximately 57 days, indicating typical investor behavior on the platform.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Most Recent News
Fulcrum Therapeutics shares plunge 49.7% after halting sickle cell drug development.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...

Inventiva temporarily suspends its stock trading on Euronext Paris ahead of a financing operation.
Inventiva, a clinical-stage biopharmaceutical company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 CEST. This suspension is at the company's request and precedes a planned financing operat...

Inventiva halts trading on Euronext Paris ahead of new financing announcement
Inventiva, a clinical-stage biopharmaceutical company, has temporarily halted trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 a.m. CEST. This pause is at the company's request and precedes a proposed financing transact...
